Table 1. Characteristics of patients who participated and who chose not to participate in the study.
| Patient Characteristic | Participant Characteristics | Non-Participant Characteristics | ||||
| Newly Diagnosed | Recurrent Disease | Consults | Newly Diagnosed | Recurrent Disease | Consults | |
| N (11072) | 3767 (34·0%) | 4711 (42·6%) | 2594 (23·4%) | 3590 (32·9%) | 4052 (37·2%) | 3256 (29·9%) |
| Age at study, median | 57±10·4 | 55±10·6 | 55±11·2 | 58±11·6 | 56±11·4 | 52±12·9 |
| Sex (%) | ||||||
| Male | 1834 (48·7%) | 1895 (40·2%) | 1212 (45·2%) | 1779 (49·6%) | 1675 (41·3%) | 1226 (37·7%) |
| Female | 1933 (51·3%) | 2816 (59·8%) | 1463 (54·5%) | 1811(50·4%) | 2377 (58·7%) | 1932 (59·3%) |
| Not Stated | 0 (0·0%) | 0 (0·0%) | 8 (0·3%) | 0 (0·0%) | 0 (0·0%) | 98 (3·0%) |
| Site of Origin (%) | ||||||
| Lung | 730 (19·4%) | 682 (14·5%) | 335 (12·5%) | 599 (16·7%) | 609 (15·0%) | 388 (11·9%) |
| Breast | 718 (19·1%) | 1102 (23·4%) | 516 (19·2%) | 729 (20·3%) | 776 (19·2%) | 687(21·1%) |
| Colorectal | 243 (6·5%) | 628 (13·3%) | 299 (11·1%) | 206 (6·7%) | 473 (11·7%) | 260 (8·0%) |
| Prostate | 527 (14·0%) | 285 (6·1%) | 241 (9·0%) | 642 (17·9%) | 275 (6·8%) | 247 (7·6%) |
| Pancreatic | 415 (11·0%) | 292 (6·2%) | 179 (6·7%) | 259 (7·2%) | 210 (5·2%) | 161 (4·9%) |
| All other Cancers | 1134 (30·1%) | 1722 (36·6%) | 1113 (41·5%) | 1155 (32·2%) | 1709 (42·2%) | 1513 (46·5%) |
| Vital Status (%) | ||||||
| Alive | 2009 (53·3%) | 1722 (36·6%) | NA | 1717 (47·8%) | 1107 (27·3%) | NA |
| Dead | 1758 (46·7%) | 2989 (63·4%) | NA | 1872 (52·1%) | 2945 (72·7%) | NA |
| Comorbidities | ||||||
| None | 1260 (33·5%) | 1828 (38·8%) | NA | 2160 (60·2%) | 2571 (63·5%) | NA |
| 1 | 687 (18·2%) | 729 (15·5%) | NA | 537 (15·0%) | 480 (11·9%) | NA |
| 2 | 551 (14·6%) | 596 (12·7%) | NA | 316 (8·8%) | 292 (7·2%) | NA |
| 3 or more | 1269 (33·7%) | 1558 (33·1%) | NA | 577 (16·1%) | 709 (17·5%) | NA |
| Best AJCC Stage (%) | ||||||
| Stage 1 | 470 (12·5%) | 69 (1·4%)a | NA | 459 (12·8%) | 55 (1·4%)a | NA |
| Stage 2 | 908 (24·1%) | 186 (3·8%)a | NA | 1024 (28·5%) | 159 (3·9%)a | NA |
| Stage 3 | 644 (17·1%) | 258 (5·3%)a | NA | 559 (15·6%) | 253 (6·2%)a | NA |
| Stage 4 | 1434 (38·1%) | 3568 (73·5%)a | NA | 1157 (32·2%) | 2789 (68·8%)a | NA |
| Unknown Stage | 311 (8·3%) | 774 (15·9%)a | NA | 391 (10·9%) | 796 (19·6%)a | NA |
a
patients re-staged following clinical presentation at CTCA.